ABBV vs. MS
ABBV (AbbVie Inc.) and MS (Morgan Stanley) are both stocks. ABBV operates in Drug Manufacturers - General (Healthcare), while MS operates in Capital Markets (Financial Services). Over the past 10 years, ABBV returned 19.10%/yr vs 27.71%/yr for MS. At a 0.27 correlation, their price movements are largely independent.
Performance
ABBV vs. MS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ABBV achieves a 1.30% return, which is significantly lower than MS's 21.88% return. Over the past 10 years, ABBV has underperformed MS with an annualized return of 19.10%, while MS has yielded a comparatively higher 27.71% annualized return.
ABBV
- 1D
- 1.32%
- 1M
- 8.24%
- YTD
- 1.30%
- 6M
- 3.65%
- 1Y
- 23.06%
- 3Y*
- 22.39%
- 5Y*
- 18.94%
- 10Y*
- 19.10%
MS
- 1D
- 0.65%
- 1M
- 11.18%
- YTD
- 21.88%
- 6M
- 21.28%
- 1Y
- 69.28%
- 3Y*
- 38.69%
- 5Y*
- 22.26%
- 10Y*
- 27.71%
ABBV vs. MS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 1.30% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
MS Morgan Stanley | 21.88% | 45.16% | 39.73% | 13.93% | -10.34% | 46.65% | 38.09% | 32.67% | -22.76% | 26.61% |
Correlation
The correlation between ABBV and MS is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2013 | 0.27 |
Over the past year, the correlation between ABBV and MS has dropped to 0.03 - well below their long-term average of 0.27, suggesting their price drivers have been diverging.
Fundamentals
ABBV:
$403.99B
MS:
$340.97B
ABBV:
$2.05
MS:
$11.41
ABBV:
110.96
MS:
18.75
ABBV:
6.43
MS:
2.84
ABBV:
14.69
MS:
3.26
ABBV:
$62.82B
MS:
$120.22B
ABBV:
$46.15B
MS:
$69.72B
ABBV:
$17.96B
MS:
$27.21B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ABBV vs. MS — Risk / Return Rank
ABBV
MS
ABBV vs. MS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for AbbVie Inc. (ABBV) and Morgan Stanley (MS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ABBV | MS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.66 | ||
| Sortino ratioReturn per unit of downside risk | -1.77 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.43 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 1.29 | 3.53 | -2.24 |
| Martin ratioReturn relative to average drawdown | 2.88 | 11.65 | -8.77 |
Loading charts...
Drawdowns
ABBV vs. MS - Drawdown Comparison
The maximum ABBV drawdown since its inception was -45.09%, smaller than the maximum MS drawdown of -88.12%. Use the drawdown chart below to compare losses from any high point for ABBV and MS.
Loading charts...
Drawdown Indicators
| ABBV | MS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -45.09% | -88.12% | +43.03% |
Max Drawdown (1Y)Largest decline over 1 year | -17.32% | -18.83% | +1.51% |
Max Drawdown (3Y)Largest decline over 3 years | -20.74% | -29.24% | +8.50% |
Max Drawdown (5Y)Largest decline over 5 years | -21.92% | -32.38% | +10.46% |
Max Drawdown (10Y)Largest decline over 10 years | -45.09% | -51.33% | +6.24% |
Current DrawdownCurrent decline from peak | -4.60% | -1.94% | -2.66% |
Average DrawdownAverage peak-to-trough decline | -10.71% | -33.69% | +22.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.75% | 5.70% | +2.05% |
Volatility
ABBV vs. MS - Volatility Comparison
The current volatility for AbbVie Inc. (ABBV) is 6.10%, while Morgan Stanley (MS) has a volatility of 8.62%. This indicates that ABBV experiences smaller price fluctuations and is considered to be less risky than MS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ABBV | MS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.10% | 8.62% | -2.52% |
Volatility (6M)Calculated over the trailing 6-month period | 17.85% | 21.46% | -3.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.31% | 25.81% | -1.50% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.89% | 28.75% | -5.86% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.73% | 31.51% | -5.78% |
Dividends
ABBV vs. MS - Dividend Comparison
ABBV's dividend yield for the trailing twelve months is around 2.96%, more than MS's 1.87% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 2.96% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
MS Morgan Stanley | 1.87% | 2.17% | 2.82% | 3.49% | 3.47% | 2.14% | 2.04% | 2.54% | 2.77% | 1.72% | 1.66% | 1.73% |
Financials
ABBV vs. MS - Financials Comparison
This section allows you to compare key financial metrics between AbbVie Inc. and Morgan Stanley. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ABBV vs. MS - Profitability Comparison
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.
MS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Morgan Stanley reported a gross profit of 20.48B and revenue of 33.15B. Therefore, the gross margin over that period was 61.8%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.
MS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Morgan Stanley reported an operating income of 7.01B and revenue of 33.15B, resulting in an operating margin of 21.2%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.
MS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Morgan Stanley reported a net income of 5.64B and revenue of 33.15B, resulting in a net margin of 17.0%.
Frequently Asked Questions
ABBV and MS have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MS has higher volatility (8.62%) compared to ABBV (6.10%). In terms of maximum drawdown, ABBV dropped -45.09% vs MS's -88.12%.
MS currently has the higher Sharpe Ratio (2.58 vs 0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ABBV and MS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer